Treatment with aromatase inhibitors for breast cancer is associated with bone loss in postmenopausal women

被引：0
|
作者：
不详
机构：
来源：
Drugs & Therapy Perspectives | 2009年 / 25卷 / 10期
关键词：
D O I：
10.2165/0042310-200925100-00007
中图分类号：
学科分类号：
摘要：
Aromatase inhibitors are a component of the standard treatment of hormone receptor-positive breast cancer in postmenopausal women. However, their use is associated with accelerated bone loss and an increased rate of fractures, in what is already an at-risk population group. It is important to screen for and prevent aromatase inhibitor-associated bone los. © 2009 Adis Data Information BV. All rights reserved.
引用
收藏
页码：23 / 26
页数：3
相关论文
共 50 条
  • [31] Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors
    Stratton, Jamie
    Hu, Xin
    Soulos, Pamela R.
    Davidoff, Amy J.
    Pusztai, Lajos
    Gross, Cary P.
    Mougalian, Sarah S.
    JOURNAL OF ONCOLOGY PRACTICE, 2017, 13 (05) : E505 - E515
  • [32] Negative Impact of Aromatase Inhibitors on Proximal Femoral Bone Mass and Geometry in Postmenopausal Women with Breast Cancer
    Su Jin Lee
    Kyoung Min Kim
    J. Keenan Brown
    Alan Brett
    Yun Ho Roh
    Dae Ryong Kang
    Byeong Woo Park
    Yumie Rhee
    Calcified Tissue International, 2015, 97 : 551 - 559
  • [33] BONE MINERAL DENSITY AND MORPHOMETRIC VERTEBRAL DEFORMITIES IN POSTMENOPAUSAL WOMEN RECEIVING AROMATASE INHIBITORS FOR BREAST CANCER
    Maldonado-Romero, L. V.
    Ahijon-Lana, M.
    Velazquez-Arce, C.
    Sifuentes Giraldo, W. A.
    Martinez Janez, N.
    Vazquez Diaz, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1201 - 1201
  • [34] Postmenopausal breast cancer, androgens, and aromatase inhibitors
    C. Campagnoli
    P. Pasanisi
    I. Castellano
    C. Abbà
    T. Brucato
    F. Berrino
    Breast Cancer Research and Treatment, 2013, 139 : 1 - 11
  • [35] Postmenopausal breast cancer, androgens, and aromatase inhibitors
    Campagnoli, C.
    Pasanisi, P.
    Castellano, I.
    Abba, C.
    Brucato, T.
    Berrino, F.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (01) : 1 - 11
  • [36] Aromatase inhibitors: Role in postmenopausal breast cancer
    Kharb, Rajeev
    Haider, Kashif
    Neha, Kumari
    Yar, Mohammad S.
    ARCHIV DER PHARMAZIE, 2020, 353 (08)
  • [37] Recommendations for the prevention of aromatase inhibitor-associated bone loss in women with breast cancer
    Aapro, M. S.
    Hadji, P.
    Brufsky, A.
    Tubana-Hulin, M.
    Guise, T.
    Body, J. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 186 - 186
  • [38] Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors
    Brufsky, Adam M.
    CLINICAL BREAST CANCER, 2007, 8 : S22 - S34
  • [39] The Early Effects of Aromatase Inhibitors on Bone Metabolism and Bone Density in Postmenopausal Women with Breast Cancer: An Interim Analysis.
    Taxel, Pamela
    Mirza, Faryal
    Fall, Pamela
    Feinn, Richard
    Tannenbaum, Susan
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [40] Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis
    Hadji, Peyman
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 69 (01) : 73 - 82
12345